News Headlines Article

Melanoma treatment employs new strategy
San Francisco Chronicle

Melanoma cells that develop resistance to a promising new treatment may overcome that through intermittent treatment, a team of researchers at UCSF has found. Researchers from UCSF, the Novartis Institutes for Biomedical Research in Emeryville and University Hospital Zurich focused on Zelboraf, a drug marketed by Genentech that was approved by the U.S. Food and Drug Administration in 2011. The oral medication inhibits melanoma’s ability to spread by attacking a genetic mutation found in about half of melanoma patients.